文献速递血脂与心血管预防

阿利西尤单抗抑制PCSK9对健康人脂蛋白代谢的影响

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
PubMed 文献 · Circulation · 2016-12-16

一项安慰剂对照两阶段研究纳入18名健康参与者,先接受2剂安慰剂(间隔2周),随后接受5剂阿利西尤单抗150 mg(间隔2周)。阿利西尤单抗使LDL-C降低55.1%、LDL-apoB降低56.3%、血浆Lp(a)降低18.7%,LDL-apoB下降源于FCR增加80.4%和PR降低23.9%。

要点

  • 阿利西尤单抗降低LDL-C 55.1%、LDL-apoB 56.3%、Lp(a) 18.7%。
  • LDL-apoB下降由FCR增加80.4%和PR降低23.9%所致。
  • IDL-apoB FCR增加46.1%,IDL向LDL转化减少27.2%。

核心结论

  • 阿利西尤单抗通过增加IDL-apoB和LDL-apoB的FCR并降低LDL-apoB的PR来降低LDL-C和LDL-apoB,结果与PCSK9抑制期间可清除IDL和LDL的LDL受体增加一致。
  • 阿利西尤单抗治疗期间apo(a) FCR增加提示LDL受体增加也可能在血浆Lp(a)降低中起作用。

研究设计与样本

  • 18名健康参与者(10名女性,8名男性)完成安慰剂对照两阶段研究。
  • 参与者接受2剂安慰剂(间隔2周),随后接受5剂阿利西尤单抗150 mg(间隔2周)。
  • 每阶段结束时测定apoB和apo(a)的FCR和PR;在10名参与者中测定餐后甘油三酯和apoB48水平。

主要发现

  • 阿利西尤单抗使超速离心分离的LDL-C降低55.1%,LDL-apoB降低56.3%,血浆Lp(a)降低18.7%。
  • LDL-apoB下降由LDL-apoB FCR增加80.4%和LDL-apoB PR降低23.9%所致。
  • LDL-apoB PR降低归因于IDL-apoB FCR增加46.1%以及IDL向LDL转化减少27.2%。
  • apo(a) FCR倾向增加(24.6%),apo(a) PR无变化。
  • 阿利西尤单抗对VLDL-apoB和VLDL甘油三酯的FCR或PR、餐后血浆甘油三酯或apoB48浓度均无影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB). Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, there have been no human studies characterizing the effects of PCSK9 inhibitors on lipoprotein metabolism. In particular, it is not known whether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lipoprotein (IDL) metabolism. Inhibition of PCSK9 also results in reductions of plasma lipoprotein (a) levels. The regulation of plasma Lp(a) levels, including the role of LDL receptors in the clearance of Lp(a), is poorly defined, and no mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date. METHODS: Eighteen (10 F, 8 mol/L) participants completed a placebo-controlled, 2-period study. They received 2 doses of placebo, 2 weeks apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart. At the end of each period, fractional clearance rates (FCRs) and production rates (PRs) of apoB and apo(a) were determined. In 10 participants, postprandial triglycerides and apoB48 levels were measured. RESULTS: Alirocumab reduced ultracentrifugally isolated LDL-C by 55.1%, LDL-apoB by 56.3%, and plasma Lp(a) by 18.7%. The fall in LDL-apoB was caused by an 80.4% increase in LDL-apoB FCR and a 23.9% reduction in LDL-apoB PR. The latter was due to a 46.1% increase in IDL-apoB FCR coupled with a 27.2% decrease in conversion of IDL to LDL. The FCR of apo(a) tended to increase (24.6%) without any change in apo(a) PR. Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandial plasma triglycerides or apoB48 concentrations. CONCLUSIONS: Alirocumab decreased LDL-C and LDL-apoB by increasing IDL- and LDL-apoB FCRs and decreasing LDL-apoB PR. These results are consistent with increases in LDL receptors available to clear IDL and LDL from blood during PCSK9 inhibition. The increase in apo(a) FCR during alirocumab treatment suggests that increased LDL receptors may also play a role in the reduction of plasma Lp(a). CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01959971.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Reyes-Soffer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation. 2016. PMID: 27986651. doi:10.1161/CIRCULATIONAHA.116.025253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。